Journal Article Summary
The article investigates the effectiveness of a new formulation of levonorgestrel butanoate (LB), an injectable contraceptive designed to suppress ovulation for an extended period. This topic is significant because current contraceptive options, such as Depo-Provera, have a limited duration of effectiveness, which can lead to discontinuation and unintended pregnancies. The study aims to determine how well this new LB formulation works in both normal and obese women, as obesity can impact the effectiveness of hormonal contraceptives.
In this pilot study, 14 women participated, with 9 having a normal body mass index (BMI) and 5 classified as obese. After receiving a single intramuscular injection of LB, the researchers monitored the participants for the return of ovulation. The findings revealed that most women returned to ovulation before the anticipated 6 months, with a notable difference between the groups: 60% of the obese participants ovulated within 90 days, while none of the normal BMI participants did so in that timeframe. No serious side effects were reported, although some participants experienced mild discomfort at the injection site and headaches.
The study has limitations, including a small sample size and a dosing error where some participants received double the intended dose. These factors may affect the reliability of the results. Patients should be aware that while the LB injection shows promise, it did not achieve the expected duration of action, particularly in obese women. It is essential for readers to discuss any contraceptive options with their healthcare provider, especially if they have concerns about weight and its impact on contraceptive effectiveness.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Edelman Alison B, Cherala Ganesh, Li Hong, Pau Francis, Blithe Diana L, Jensen Jeffrey T. Levonorgestrel butanoate intramuscular injection does not reliably suppress ovulation for 90 days in obese and normal BMI women: a pilot study. Contraception 2016. DOI: 10.1016/j.contraception.2016.07.018. PMID: 27475035. PMCID: PMC5140699.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive --- Perrigo
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive --- Perrigo is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. No prescription required for eligible over-the-counter purchases.
